SANES

10.82

+3.17%↑

BBVA

20.08

+3.67%↑

BNP

92.72

+3.1%↑

CABK

11.68

+2.05%↑

INGA

27.14

+2.61%↑

SANES

10.82

+3.17%↑

BBVA

20.08

+3.67%↑

BNP

92.72

+3.1%↑

CABK

11.68

+2.05%↑

INGA

27.14

+2.61%↑

SANES

10.82

+3.17%↑

BBVA

20.08

+3.67%↑

BNP

92.72

+3.1%↑

CABK

11.68

+2.05%↑

INGA

27.14

+2.61%↑

SANES

10.82

+3.17%↑

BBVA

20.08

+3.67%↑

BNP

92.72

+3.1%↑

CABK

11.68

+2.05%↑

INGA

27.14

+2.61%↑

SANES

10.82

+3.17%↑

BBVA

20.08

+3.67%↑

BNP

92.72

+3.1%↑

CABK

11.68

+2.05%↑

INGA

27.14

+2.61%↑

Home・Akcijų sąrašas・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

173 1.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

170.7

Max

173.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	41M 88M
Pardavimai	-11M 762M
P/E Sektoriaus vid.	57.428 58.236
Pelnas, tenkantis vienai akcijai	1.17
Pelno marža	11.569
Darbuotojai	10,456
EBITDA	26M 225M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+36.5% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-23

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-2.7B 15B
Ankstesnė atidarymo kaina	171.83
Ankstesnė uždarymo kaina	173

Naujienos nuotaikos

By Acuity

21%

79%

6 / 438 reitingas Finance

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-25 08:24; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026-05-25 21:22; UTC

Uždarbis

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026-05-25 20:50; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:20; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:01; UTC

Rinkos pokalbiai

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026-05-25 14:43; UTC

Rinkos pokalbiai

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026-05-25 14:15; UTC

Rinkos pokalbiai

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026-05-25 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-25 12:58; UTC

Rinkos pokalbiai

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026-05-25 12:56; UTC

Rinkos pokalbiai

Uždarbis

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-25 12:34; UTC

Rinkos pokalbiai

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026-05-25 12:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero's Assets Look Strategic -- Market Talk

2026-05-25 11:00; UTC

Rinkos pokalbiai

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026-05-25 10:19; UTC

Rinkos pokalbiai

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026-05-25 10:05; UTC

Uždarbis

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026-05-25 10:04; UTC

Uždarbis

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026-05-25 10:03; UTC

Uždarbis

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026-05-25 10:02; UTC

Uždarbis

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026-05-25 10:01; UTC

Uždarbis

Tenaga Nasional 1Q Net Up 3.7% on Year

2026-05-25 10:00; UTC

Uždarbis

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q EPS MYR0.1883

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Rev MYR17.1B

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Net MYR1.1B

2026-05-25 09:38; UTC

Rinkos pokalbiai

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026-05-25 08:55; UTC

Rinkos pokalbiai

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

36.5% į viršų

12 mėnesių prognozė

Vidutinis 233 EUR 36.5%

Aukščiausias 262 EUR

Žemiausias 210 EUR

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Sartorius Stedim Biotech. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

6 / 438 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.